A recent review in Clinical Advances in Hematology & Oncology spotlights promising developments in gastrointestinal oncology — especially for colorectal and pancreatic cancers, where late-stage diagnoses have long limited options. Highlights include fruquintinib for refractory metastatic CRC, the tucatinib + trastuzumab combination for HER2-positive CRC, and expanded uses for trifluridine-tipiracil in combination regimens.
Trending
- Are we sleepwalking into AI disruption in GI?
- AI Digital Twins Are Helping People Manage Diabetes and Obesity (WIRED)
- 3 Healthcare Threats That Will Soon Become Too Big To Solve (Forbes)
- From GLP-1s to engineered probiotics: New research highlights evolving IBD care (AGA)
- Physician consolidation squeeze: Rising costs and tight cash flow are reshaping practice growth (Physicians Practice)
- The International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of gut health (Nature Reviews Gastroenterology & Hepatology)
- Medical Malpractice: Staying Out of Trouble (GI & Endoscopy News)
- Evaluating Benefits of AI During Colonoscopy (GI & Endoscopy News)
